Venous thromboembolism

Management of venous thromboembolism in COVID-19

An overview of the current guidelines on anticoagulation management of COVID-19 associated thromboembolism.…

How pharmacists have taken over the care of venous thromboembolism patients in our area

Kieron Power describes the humble beginnings of his clinic, which has developed into the point of care for all patients with venous thromboembolism in his health board.…

Cancer-associated thrombosis

Venous thromboembolism is a complication of cancer that pharmacists should understand to ensure that their patients have the best possible outcomes.  …

Acute coronary syndrome: risk factors, diagnosis and treatment

This overview describes the different management options for acute coronary syndrome and how pharmacists can support patients with the condition.…

Prevention of venous thromboembolism in hospitalised patients

Pharmacists should note the National Institute for Health and Care Excellence’s updated guidance on use of pharmacological thromboprophylaxis in a range of hospitalised patient groups.…

Oral preparations of HRT increase risk of VTE, study finds

Most oral preparations of hormone replacement therapy (HRT) are associated with a higher risk of venous thromboembolism (VTE), a study published in The BMJ has found.…

Antidepressants linked with increased risk of VTE

Depression and use of antidepressants are each associated with an increased risk of venous thromboembolism, a study has revealed. Although the mechanism underlying these associations is not yet understood.…

Primary-care overprescribing of rivaroxaban in patients without atrial fibrillation

There is a national prescribing trend for rivaroxaban (Xarelto; Bayer), one of four drugs known as direct oral anticoagulants (DOACs), and prescription is steadily rising. The drug has six licensed indications, with four different dosages and at least five possible durations of therapy, depending on…

Newer anticoagulants have no more safety risks than warfarin

Treating venous thromboembolism with direct oral anticoagulants creates no greater risk of major bleeding or death in the first 90 days of treatment compared with warfarin.…

Rivaroxaban more effective than aspirin for preventing blood clots, study results suggest

Rivaroxaban is as safe as aspirin and more effective at preventing recurrent venous thromboembolism (VTE) in patients who were in equipoise for continued anticoagulants, a study shows.…